Study of sul-238 for early untreated parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests whether an experimental medicine called SUL-238 can improve energy levels in the brain cells of people with early, untreated Parkinson's. It uses a special type of MRI to see if the medicine affects brain energy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Parkinson's disease within the last year.
- You have not yet taken any Parkinson's disease medication.
- Your Parkinson's symptoms are mild — you can walk independently, and balance is mostly fine.
- You are 40 years or older.
- You can have an MRI scan (no metal implants, pacemaker, etc.).
- You are not taking high-dose vitamin E or other supplements that affect mitochondria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication for people with early-onset Parkinson's disease. It aims to see if the drug safely improves motor symptoms and quality of life compared to a placebo.
This study tests a new tablet called ENERGI-F705 to see if it helps reduce Parkinson's disease symptoms and is safe to take. You'll need to have had Parkinson's for at least 2 years and be on standard Parkinson's medications.
This is an early-stage study testing a new experimental medicine called SST001 in people with Parkinson's disease (PD) and multiple system atrophy (MSA), as well as healthy volunteers. The study checks whether SST001 is safe, how the body processes it, and where it goes in the body using imaging scans.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.